Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Farmers Insurance
Chinese Patent Office
Johnson and Johnson
Dow
Harvard Business School
Medtronic
Teva
Baxter
UBS

Generated: January 18, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,309,229

« Back to Dashboard

Which drugs does patent 9,309,229 protect, and when does it expire?

Patent 9,309,229 protects ZYKADIA and is included in one NDA.

This patent has thirty-seven patent family members in twenty-nine countries.
Summary for Patent: 9,309,229
Title:Crystalline forms of 5-chloro-N2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-N4-[2-(propan- e-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine
Abstract: The present invention describes specific crystalline forms of 5-chloro-N-(2-isopropoxy-5-methyl-4-(piperidin-4-ylphenyl)-N-2-(isopropyl- sulfonyl)phenyl)-2,4-diamine. The present invention further relates to methods for preparing said crystalline forms, pharmaceutical compositions comprising said crystalline forms, and methods of using said crystalline forms and pharmaceutical compositions to treat disease.
Inventor(s): Feng; Lili (Pine Brook, NJ), Gong; Baoqing (Morris Plains, NJ), Karpinski; Piotr H. (Lincoln Park, NJ), Waykole; Liladhar Murlidhar (Succasunna, NJ)
Assignee: Novartis AG (Basel, CH)
Application Number:13/993,217
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 9,309,229

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Novartis Pharms Corp ZYKADIA ceritinib CAPSULE;ORAL 205755-001 Apr 29, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 9,309,229

PCT Information
PCT FiledDecember 15, 2011PCT Application Number:PCT/US2011/065030
PCT Publication Date:June 21, 2012PCT Publication Number: WO2012/082972

International Patents Family Members for US Patent 9,309,229

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Peru 06982014 ➤ Subscribe
New Zealand 610713 ➤ Subscribe
Mexico 338210 ➤ Subscribe
Mexico 2013006952 ➤ Subscribe
Morocco 34771 ➤ Subscribe
Lithuania 2651918 ➤ Subscribe
South Korea 20130130022 ➤ Subscribe
Japan 5916752 ➤ Subscribe
Japan 2013545812 ➤ Subscribe
Israel 226474 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Merck
Express Scripts
Dow
Fuji
McKesson
Novartis
US Department of Justice
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot